What are the harms of COPD to patients?
Feb 15, 2022
Source: Cainiu Health
Dr. Wang Xingsheng
Introduction
What are the harms of COPD to patients?
COPD is an incurable chronic disease that significantly impairs patients’ life expectancy and quality of life. First, physical activity becomes severely limited, rendering patients unable to perform physically demanding tasks in daily life. In long-standing COPD, chronic systemic hypoxia develops; pulmonary hypoxia, in particular, predisposes patients to cor pulmonale, which may ultimately progress to heart failure.
COPD generally refers to chronic obstructive pulmonary disease (COPD). COPD is a common, chronic condition characterized by airflow obstruction, typically resulting from chronic bronchitis and/or emphysema. It may progress to cor pulmonale and respiratory failure. So, what are the health risks posed by COPD to patients? Let’s explore them below.
What Are the Health Risks of COPD to Patients?
COPD is an incurable chronic disease that significantly impairs both life expectancy and quality of life. First, patients experience limitations in physical activity and are often unable to perform physically demanding tasks in daily life. Long-standing COPD leads to systemic hypoxia, particularly within the lungs, which predisposes patients to cor pulmonale and ultimately heart failure. In the terminal stages of the disease, life-threatening complications—such as respiratory failure—may occur. Moreover, because COPD cannot be cured, it imposes substantial physical and psychological burdens on patients; some may develop chronic insomnia, anxiety, or even depression.
How Is COPD Treated?
Pharmacological treatment for COPD includes the following classes of medications:
1. Anticholinergic agents, available as either long-acting or short-acting formulations—for example, ipratropium bromide and tiotropium bromide.
2. Adrenergic receptor agonists—for example, salbutamol and terbutaline.
3. Xanthine derivatives—for example, aminophylline.
4. Corticosteroids—for example, budesonide, hydrocortisone, and fluticasone.
5. Expectorants/mucolytics—for example, carbocisteine, bromhexine, and ambroxol.
Pharmacotherapy for COPD must be guided by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification system, which assesses disease severity and determines appropriate stepwise management. Regardless of whether symptoms improve, long-term adherence to medication is essential.
Patients with COPD must quit smoking definitively, as tobacco smoking is one of the most critical factors contributing to the onset, progression, and exacerbation of COPD. Adjunctive strategies—such as food substitution therapy—may support smoking cessation. In daily life, patients are encouraged to engage in moderate physical exercise—including tai chi, cycling, and swimming—to enhance lung capacity and overall physical resilience.
We hope the above information is helpful to you.
